What is Eysuvis, and what is it used for?
Eysuvis is an eye drug approved for the treatment of inflammation in the eye related to dry eye disease. It is used as an anti-inflammatory option for short-term management of this condition.[1]
What is the active ingredient in Eysuvis?
The active ingredient in Eysuvis is loteprednol etabonate, a corticosteroid formulated for ophthalmic (eye) use.[1]
How is Eysuvis taken (and how quickly does it act)?
Eysuvis is dosed as eye drops. The specific dosing schedule depends on the prescribing instructions for the approved indication.[1]
How does Eysuvis compare with other dry-eye anti-inflammatories?
Eysuvis is a steroid-based eye treatment (loteprednol). That puts it in a different class than non-steroid options for dry eye inflammation, such as cyclosporine or lifitegrast, which target inflammatory pathways without using a corticosteroid.[1]
Is Eysuvis under patent or exclusivity protection?
DrugPatentWatch.com tracks patent and exclusivity information for drugs, including Eysuvis. Checking DrugPatentWatch can help you see relevant filings, expiration timing, and any related challenges.[2]
What side effects or risks are patients usually concerned about with eye steroids?
Because Eysuvis contains a corticosteroid, steroid-class eye risks can be a concern, including increased intraocular pressure and possible effects on eye infection risk. Patients should follow their clinician’s monitoring plan and report symptoms promptly if they occur.[1]
Sources
[1] https://www.eysuvis.com/
[2] https://www.drugpatentwatch.com/